Ignite Creation Date:
2024-05-06 @ 1:46 PM
Last Modification Date:
2024-10-26 @ 1:19 PM
Study NCT ID:
NCT04113616
Status:
TERMINATED
Last Update Posted:
2024-03-22
First Post:
2019-10-01
Brief Title:
An Open-Label Multicenter Phase 1b2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine LDAC or Decitabine in Patients With Acute Myeloid Leukemia AML
Sponsor:
Kartos Therapeutics Inc
Organization:
Kartos Therapeutics Inc
Organization Data
Organization:
Kartos Therapeutics Inc
Class:
INDUSTRY
Study ID:
KRT-232-104
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Kartos Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None